Summit Therapeutics Inc

SMMT is in an early Stage 1 consolidation following a terminal decline, with price stabilizing above rising 9/21 EMAs. The Bullish Pivot Point pattern signals structural repair and a shift toward upward mean reversion. OS readings and RSI support a tactical entry. With medium- and long-term trends intactly up, execution now via pullback into the EMA support zone is appropriate.

• ↑Phase III Harmony trial shows 34% reduction in death risk vs PD-1/chemo in NSCLC
• ↑Q4’25 cash of $713.4M with zero debt provides funding through key readouts
• ↓Weak profitability metrics highlight low returns amid high R&D spend